A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Inclusion Criteria: * Be 20 years of age at the time the informed consent form is signed and of Japanese ethnicity (ie, both parents are native Japanese and were born in Japan). * Have a solid tumor that has progressed on standard treatment: * For patients enrolled in the dose-escalation portion, has confirmed solid tumor that is locally recurrent or metastatic * For patients enrolled in the dose-expansion portion, has high-grade serous ovarian cancer, or BRCA 1/2 mutated breast cancer, or other solid tumor with BRCA 1/2 or related gene mutation * Have to have evaluable disease (i.e. disease can be followed on scans.) * Be willing and able to fast for at least 14 hours Exclusion Criteria: * Active second malignancy * Prior treatment with any PARP inhibitor * Symptomatic and/or untreated CNS metastases * Women who are breastfeeding or pregnant * Pre-existing duodenal stent and/or any gastrointestinal disorder that would interfere with drug absorption * Requires regular blood transfusions